An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.

Authors

Olumide B. Gbolahan

Emory University School of Medicine, Atlanta, GA

Olumide B. Gbolahan , Mehmet Akce , Darryl Alan Outlaw , Grant Richard Williams , Sushanth Reddy , Jason Denbo , Richard D. Kim , Bassel F. El-Rayes , J. Bart Rose III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.

First Author: Vaibhav Sahai

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.

First Author: William Joseph Chapin